Division of Genetics, Department of Pediatrics, Program in Immunology, Institute for Genomic Medicine, UCSD Center for AIDS Research, University of California San Diego, 9500 Gilman Drive MC 0762, La Jolla, CA 92093, USA.
Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Nucleic Acids Res. 2022 Jul 8;50(12):6687-6701. doi: 10.1093/nar/gkac464.
The retrovirus human immunodeficiency virus-1 (HIV-1) is the causative agent of AIDS. Although treatment of HIV/AIDS with antiretroviral therapy provides suppression of viremia, latent reservoirs of integrated proviruses preclude cure by current antiviral treatments. Understanding the mechanisms of host-viral interactions may elucidate new treatment strategies. Here, we performed a CRISPR/Cas9 transcriptional activation screen using a high-complexity, genome-wide sgRNA library to identify cellular factors that inhibit HIV-1 infection of human CD4+ T cells. MT4 cells were transduced with a CRISPR/Cas9 sgRNA library and infected with nef-deficient HIV-1NL4-3 expressing ganciclovir-sensitive thymidine kinase, thus enabling selection of HIV-1-resistant cells for analysis of enriched sgRNAs. After validation of screen hits, multiple host factors essential for HIV-1 infection were identified, including SET (SET nuclear proto-oncogene) and ANP32A (acidic nuclear phosphoprotein 32A, PP32A), which together form a histone acetylase inhibitor complex. Using multiple human cell lines and peripheral blood mononuclear cells (PBMCs) from healthy donors and HIV-1-infected individuals, we demonstrate that SET depletion increased HIV-1 infectivity by augmenting DNA integration without significantly changing sites of integration. Conversely, SET overexpression decreased HIV-1 integration and infectivity. SET protein expression was significantly reduced in PBMCs from HIV-1-infected individuals and was downregulated by HIV-1 infection of healthy donor cells in vitro. Notably, HIV-1-induced downregulation of SET could be alleviated by inhibition of the protease granzyme A. Altogether, we have identified cellular inhibitors of HIV-1 infection on a genome-wide scale, which affords new insight into host-virus interactions and may provide new strategies for HIV-1 treatment.
逆转录病毒人类免疫缺陷病毒 1(HIV-1)是艾滋病的致病因子。尽管使用抗逆转录病毒疗法治疗 HIV/AIDS 可抑制病毒血症,但整合前病毒的潜伏储库排除了当前抗病毒治疗的治愈可能。了解宿主-病毒相互作用的机制可能阐明新的治疗策略。在这里,我们使用高复杂度的全基因组 sgRNA 文库进行了 CRISPR/Cas9 转录激活筛选,以鉴定抑制人类 CD4+T 细胞中 HIV-1 感染的细胞因子。MT4 细胞被 CRISPR/Cas9 sgRNA 文库转导,并感染表达更昔洛韦敏感胸苷激酶的 nef 缺陷型 HIV-1NL4-3,从而能够选择 HIV-1 抗性细胞来分析富集的 sgRNA。在验证筛选命中后,鉴定出多个对 HIV-1 感染至关重要的宿主因子,包括 SET(SET 核原癌基因)和 ANP32A(酸性核磷蛋白 32A,PP32A),它们共同形成组蛋白乙酰转移酶抑制剂复合物。使用多种人类细胞系和来自健康供体和 HIV-1 感染个体的外周血单核细胞(PBMC),我们证明 SET 耗竭通过增强 DNA 整合而增加 HIV-1 感染力,而不会显著改变整合位点。相反,SET 过表达会降低 HIV-1 整合和感染力。HIV-1 感染个体的 PBMC 中 SET 蛋白表达明显降低,并且体外 HIV-1 感染健康供体细胞会下调 SET 表达。值得注意的是,HIV-1 诱导的 SET 下调可以通过抑制蛋白酶 granzyme A 来缓解。总的来说,我们已经在全基因组范围内鉴定了 HIV-1 感染的细胞抑制剂,这为宿主-病毒相互作用提供了新的见解,并可能为 HIV-1 治疗提供新策略。